Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea Approves Second Biosimilar Infliximab

This article was originally published in PharmAsia News

Executive Summary

After receiving the green light for its version of etanercept a few months ago, Samsung Bioepis has gained a second biosimilar regulatory approval in South Korea as it aims to catch up with frontrunner Celltrion. Renflexis is the second infliximab biosimilar to be approved in the country after Celltrion's Remsima.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts